https://www.live-feeds.com/feed/new-mrna-vaccine-reduces-risk-of-melanoma-recurrence-by-over-40-percentContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/new-mrna-vaccine-reduces-risk-of-melanoma-recurrence-by-over-40-percenthttps://www.live-feeds.com/feed/new-mrna-vaccine-reduces-risk-of-melanoma-recurrence-by-over-40-percent#u166162Sat, 31 Oct 2026 14:11:38 +0000A personalized mRNA cancer vaccine called intismeran, developed by Moderna and Merck, cut the risk of melanoma recurrence or death by 42 percent when combined with standard immunotherapy. Results from the randomized phase 3 INTerpath-001 trial showed the bespoke treatment also lowered the risk of distant metastasis or death by 38 percent in patients with completely resected high-risk melanoma. The long-awaited findings were released by the pharmaceutical companies and scheduled for presentation at the ESMO Congress.Why it mattersThe trial data marks a foundational shift in oncology by using me